Lewes, DE -- (SBWIRE) -- 11/17/2015 -- Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015report depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.

This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.

There are 13+ active companies dealing with 70+ siRNA therapies. Mostly siRNA is being studied for oncology area with 24 siRNA therapies under development by major pharma companies followed by 11 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 28 siRNA are in clinical stage of development with many mid-stage products.

Scope
- Coverage of global siRNA therapies under development across the globe
- Competitive landscape of investigational products for key players and key therapy areas
- The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies.
- Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
- Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline.
- Report analyzes the different emerging delivery technologies by companies and products under development.

Reasons to buy
The siRNA report covers complete Pipeline intelligence and understanding over therapeutics development for siRNA.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for siRNA
- The siRNA report helps to develop a better understanding of the emerging technologies by the recent acquisitions which are driving the siRNA market
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding siRNA pipeline in-depth
- Identifying the upcoming leaders in the siRNA market in the coming year

Spanning over "Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015" report covers Executive Summary, Introduction, Commercial Assessment, Companies & Technologies, Pipeline Overview, Appendix.

Find more information Visit at: http://www.marketresearchreports.com/delveinsight/small-interfering-rna-sirna-therapeutics-competitive-landscape-technology-and-pipeline

Find all Diagnostics reports at: http://www.marketresearchreports.com/diagnostics

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions